The effect of co-administration of zolpidem with fluoxetine: Pharmacokinetics and pharmacodynamics

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 4, 1996, Pages 178-183

  Piergies, A A ^a   Sweet, J ^a   Johnson, M ^a   Roth Schechter, B F ^b   Allard, S ^c  

^a EVANSTON HOSPITAL   (United States)

^b Boston Res and Science Consulting   (United States)

^c Lorex Pharmaceuticals   (United States)

Author keywords

Drug interactions; Fluoxetine; Zolpidem

Indexed keywords

FLUOXETINE; NORFLUOXETINE; ZOLPIDEM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSOMNIA; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PSYCHOMOTOR PERFORMANCE; SOMNOLENCE; STATISTICAL ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUOXETINE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PSYCHOMOTOR PERFORMANCE; PYRIDINES; SEROTONIN UPTAKE INHIBITORS;

EID: 0030005721     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bech P 1993 Acute therapy of depression. J Clin Psychiatry 54 (Suppl): 18-27
2. Cavanaugh J, Schneck D, Eason C et al 1994 Lack of effect of fluoxetine on the pharmacokinetics PK and pharmacodynamics PD of estazolam. Clin Pharmacol Ther 55: 141
3. Ciraulo DA, Shatter RI 1990 Fluoxetine drug-drug interactions: II. J Clin Psychopharmacol 103: 213-218
4. Cohn CK, Shrivastava R, Mendels J et al 1990 Double-blind multi-center comparison of sertraline and amitriplyline in elderly depressed patients. J Clin Psychiatry 51 (Suppl B): 28-33
5. Cook MD, Conner J 1995 Retrospective review of hypnotic use in combination with fluoxetine or sertraline. Clin Drug Invest 94: 212-216
6. Finney DJ 1971 Statistical method in biological assay 2nd edn. Hafner Press, New Jersey, pp 27-29
7. Fleishaker JC, Hulst LK 1991 Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl) 104: 323-327
8. Greenblatt DJ, Preskorn SH, Colreau MM et al 1992 Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 52: 479-486
9. Guze BH, Gitlin M 1994 New antidepressants and the treatment of depression. J Fam Pract 381: 49-57
10. Harvengt C, Hulhoven R, Desager J et al 1988 Drug interactions investigated with zolpidem. In: Sauvanet JP, Langer SL, Morselli PL (eds) azopyridines in sleep disorders: a novel experimental and therapeutic approach. LERS monograph series (Vol 6). Raven Press, New York, pp 165-173
11. Messiha FS 1993 Fluoxetine: Adverse effects and drug-drug interactions. Clin Toxicol 314: 603-630
12. Moltke von LL, Greenblatt DJ, Shader RI 1992 In vitro inhibition of alprazolam ALP oxidation by fluoxetine F and norfluoxetine NF. J Clin Pharmacol 328: 764
13. Moltke von LL, Greenblatt DJ, Cotreau-Bibbo MM et al 1994 Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268: 1278-1283
14. Neylan TC 1995 Treatment of sleep disturbances in depressed patients. J Clin Psychiatry 56 (Suppl): 56-61
15. Nicholson AN, Pascoe PA 1988 Studies on the modulation of the sleepwakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacology 27: 597-602
16. Pichard L, Gillet G, Bonfils C et al 1995 Oxidative metabolism of zolpidem by human liver cytochrome P450s. Mol Pharmacol in press
17. Rickels K, Schweizer E 1990 Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 51 (Suppl B): 9-12
18. Roehrs T, Kribbs N, Zorick F et al 1986 Hypnotic residual effects of benzodiazepines with repeated administration. Sleep 92: 309-316
19. Roth, Hauri P, Zorick F et al 1985 The effects of midazolam and temazepam on sleep and performance when administered in the middle of the night. J Clin Psychopharmacol 52: 66-69
20. Schenck CH, Mahowald MW, Kim SW et al 1992 Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 15: 226-235
21. Stark P, Hardison CD 1985 A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 46: 53-58
22. Steven HY et al 1990 Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. J Chromatogr 499:608608
23. Stokes PE 1993a A primary care perspective on management of acute and long-term depression. J Clin Psychiatry 54 (Suppl): 74-84
24. Stokes PE 1993b Fluoxetine: a five-year review. Clin Ther 15: 216-243
25. Thénot JP, Hermann P, Durand A 1988 Pharmacokinetics and metabolism of zolpidem in various animal species and in humans. In: Sauvanet JP, Langer SZ, Morselli PL (ed) Imidazopyridines in sleep disorders. Raven Press, New York, 139-153
26. Varhe A, Olkkola KT, Neuvonen PJ 1994 Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Phamacol Ther 56: 601-607
27. Wright CE, Lasher-Sisson TA, Steenwyk RC et al 1992 A pharmacokinetic evaluation of the combined administration of triazolam. Pharmacotherapy 12: 103-106